Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025Business Wire • 08/14/25
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law FirmPRNewsWire • 08/12/25
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025Business Wire • 08/11/25
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial ResultsThe Motley Fool • 07/22/25
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law FirmBusiness Wire • 07/14/25
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks RemainSeeking Alpha • 07/04/25
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to TradeZacks Investment Research • 07/02/25
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant TumorsBusiness Wire • 06/30/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTGlobeNewsWire • 06/23/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTGlobeNewsWire • 06/10/25
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceBusiness Wire • 06/05/25
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a TurnaroundZacks Investment Research • 06/03/25